Ophthalmic bevacizumab for wet macular degeneration
Raised to date
No sales reported yet
of $37M offered across 2 Form D filings
Outlook Therapeutics is a pioneering biopharmaceutical company specializing in the development and commercialization of ophthalmic medications. The company is committed to addressing significant unmet medical needs in the treatment of retinal diseases through innovative therapeutic solutions.
Outlook Therapeutics distinguishes itself by developing the first FDA-approved ophthalmic formulation of bevacizumab, directly addressing a current gap in the treatment of retinal diseases like wet AMD.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| May 7, 2026 | Equity | None sold/ $5M | Form D |
| Jan 27, 2025 | Equity | None sold/ $32M | Form D |
Retinal Disease Treatment
This product is an innovative ophthalmic formulation of bevacizumab specifically designed to meet FDA standards. It is intended for the treatment of various retinal diseases, particularly wet age-related macular degeneration.
Built for
Ophthalmologists and Retinal Specialists
